Universal Minimal Residual Disease Quantification Using Consensus Primers and High-Throughput Igh Sequencing Predicts Post-Transplant Cll Relapse Better Than Patient-Specific PCR  by Logan, A.C. et al.
S288 Poster Session I226
MINIMAL LATE EFFECTS FOLLOWING REDUCED INTENSITY TRANS-
PLANT FOR NON-MALIGNANT DISORDERS
Madden, L.M.1, Shenoy, S.1, Murray, L.1, Witty, S.2, Hayashi, R.J.1
1Washington University School of Medicine, Saint Louis, MO; 2Univer-
sity of Missouri School of Medicine, Columbia, MO
Allogeneic transplant is the only cure for many non-malignant
life-threatening disorders. Reduced intensity conditioning regi-
mens are increasingly employed prior to stem cell transplantation,
but little is known about the late effects of these regimens. We
present here the late effects of a preparative regimen consisting
of Campath-1H, Fludarabine, and Melphalan beyond two years
following transplantation. We have found that the regimen itself
has very few late effects. Using CTCAE v. 4.03 for criteria to clas-
sify the severity of the late effects, out of twenty patients studied,
five patients experienced a grade 1, two patients a grade 2, and
two patients a grade 3 toxicity; no patients experienced a grade
4 toxicity, and one patient experienced a grade 5 toxicity. The
most common regimen-associated toxicity, found in 15% of pa-
tients, was an acquired autoimmune disorder affecting red cells
and neutrophils. One patient developed extensive, chronic
GVHD leading to multi organ system dysfunction, severe linear
growth deceleration, and eventual death. 70% of patients fully en-
grafted, 15% had stable mixed chimerism, and 15% had secondary
graft rejection, one of whom required a second, myeloablative
transplant. The other two were rescued with donor lymphocyte
infusions. There was only one patient with transplant-associated
growth failure, and puberty was acheived in the 25% of patients
who were of age to pass through puberty during and after trans-
plant, indicating that gonadal function was preserved in this pop-
ulation. We did not observe transplant-associated cognitive
impairment. There were two deaths (10%), one (5%) of which
was transplant-related, one (5%) was attributable to a complication
of his underlying disease. Thus, this non-myeloablative regimen
was associated with minimal toxicity two years beyond the trans-
plant procedure, making it an attractive option for patients with,
nonmalignant diseases.LEUKEMIA227
UNIVERSAL MINIMAL RESIDUAL DISEASE QUANTIFICATION USING CON-
SENSUS PRIMERS AND HIGH-THROUGHPUT IGH SEQUENCING PREDICTS
POST-TRANSPLANT CLL RELAPSE BETTER THAN PATIENT-SPECIFIC PCR
Logan, A.C.1, Zhang, M.B.2, Faham, M.3, Carlton, V.3, Zheng, J.3,
Moorhead, M.3, Willis, T.3, Jones, C.D.2, Waqar, A.N.2,
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Methods for broadening the availability of minimal residual dis-
ease (MRD) quantification in chronic lymphocytic leukemia
(CLL) are needed to improve patient management. Here, we re-
port the performance of consensus primed PCR to amplify immu-
noglobulin heavy chain (IGH) loci from polyclonal B cells in
peripheral blood, followed by high-throughput sequencing
(IGH-HTS) to ascertain CLL burden in patients treated with re-
duced intensity allogeneic hematopoietic cell transplant (HCT).
We achieved 10e-6 MRD sensitivity and found this approach pro-
vides better prediction of relapse than allele-specific quantitative
PCR (ASO-PCR).
We amplified IGH loci from genomic DNA extracted from
PBMC (median input 1.4x10e6 cells; range 0.2-23.7x10e6) using
consensus V and J segment primers. IGH molecules were se-
quenced with one million or more dedicated reads using Illu-
mina HiSeq and clonotypes were quantified with Sequenta
HTS bioinformatics. 289 samples collected prospectively from
42 patients at 10 post-HCT time points (range 0-1090 days)
were analyzed.
CLL-specific IGH clonotypes were identified for 37 patients ei-
ther by Sanger sequencing performed for pre-transplant prognosti-
cation, or by IGH-HTS using disease bearing samples. Fivepatients did not have samples with sufficient disease burden to iden-
tify the CLL clone and have been excluded from analysis. 24 patients
were assessed by ASO-PCR and IGH-HTS, 13 by IGH-HTS alone.
We observed no failures of the IGH-HTS technique to recover
CLL-specific IGH clones, even in patients with somatically mutated
CLL.
With median follow-up of 927 days (range 297-2265 days), 18 pa-
tients (49%) relapsed and 7 (19%) died. Of 17 patients positive for
MRD by IGH-HTS between 270 to 365 days post-HCT, 100% re-
lapsed, whereas 1 of 12 MRD negative patients (8.3%) relapsed (p5
0.0001). In contrast, ASO-PCR negativity during this time frame
was not associated with sustained remission (p 5 0.21). Owing to
its higher sensitivity, the median time to MRD negativity was longer
with IGH-HTS compared with ASO-PCR (365 versus 270 days).
80% of patients who achieved ASO-PCR negativity at any time,
but who never subsequently achieved negativity by IGH-HTS,
relapsed.
IGH-HTS provides heretofore unachievable MRD sensitivity for
patients with CLL. The highly prognostic value of achieving MRD
negativity with 10e-6 sensitivity within one year post-HCTmay pro-
vide a benchmark for treatment success and a basis for further ther-
apy in patients failing to achieve this status.228
FREQUENCY OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTA-
TION AMONG HIGH-RISK AML PATIENTS IN FIRST COMPLETE REMIS-
SION AT AN ACADEMIC CENTER
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Background: Allogeneic hematopoietic cell transplantation
(HCT) likely prolongs survival in high-risk adults with acute my-
eloid leukemia (AML) in first complete remission (CR1). Prior
studies, however, suggest that only about 15% of AML patients
age $50 with abnormal cytogenetics who entered CR1 at an aca-
demic cancer center received a reduced intensity HCT in CR1
(Estey et al., Blood 2007;109:1395-1400). In this study, only
HLA-matched siblings were primarily used as donors, raising
the question of the frequency with which HCT is performed in
adults of all ages entering CR1 if unrelated donors as well as sib-
lings are utilized. Here we address this question and compare
high- or intermediate-risk AML patients who did and did not re-
ceive HCT while in CR1.
Methods: Between Jan, 1 2008 and March 1, 2011, 244 patients
received treatment for newly-diagnosed AML at our Center and
who achieved CR or CRi [98/117 (84%) in CR and 19/117
(16%) in CRi]. Because HCT is generally not recommended/un-
dertaken in patients age .75 or who have favorable cytogenetic
risk [inversion 16, t(8,21), or t(15;17)] or who are NPM1 mutated
and FLT3 wild-type, we excluded such patients, leaving 117 with
high- or intermediate-risk AML in CR1. Logistic regression was
used to distinguish characteristics associated with receiving HCT
in CR1.
Results: Seventy-nine AML patients (68%; 95% CI 59-76%) re-
ceived HCT in CR1 at a median of 5.1 months (range, 1.2-20
months) from their CR1 date. Characteristics of patients who re-
ceived or did not receiveHCT inCR1 are shown in the Table below:
Table. HCT vs No HCT in CR1
P-value
HCT
(79 pts)
No HCT
(38 pts)logistic
regressionMean Age (range) 53 (18-75) 55 (24-73) 0.54
Mean Performance status
at CR1 (range)1.1 (1-2) 1.5 (1-4) 0.005Mean HCT-CI (range) 1.7 (0-11) 1.9 (0-7) 0.65
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